Feeds:
Posts
Comments

Posts Tagged ‘nuvaring’

*****

TODAY’S NEWS

Great news for hepatitis C treatment (and Vertex) – Adding the investigational drug telaprevir to standard treatment for hepatitis C infection cures about half the patients willing to give therapy a second try. That compares to a cure rate of just 14 percent among those who were retreated with the standard regimen, according to researchers at the Duke Clinical Research Institute (DCRI)more

Teva gets approval to market generic versions of two key Merck cardio drugs (Cozaar and Hyzaar).

Sanofi makes a long-term investment into a cool-sounding diabetes treatment (pre-Phase 1).

Is Nuvaring a pinata for plaintiff’s attorneys? – Merck’s Nuvaring contraceptive appears to be headed for the same fate as Bayer’s Yaz pill and Johnson & Johnson’s Ortho Evra contraceptive patch: It’s becoming a pinata for plaintiffs’ lawyers who allege the device is more dangerous than older, equally effective products on the marketmore

RECOMMENDED

eMarketing/PR– We can recommend best-in-class partners/agencies for your needs.  Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

Social Media – Nine things Pharma should learn about Social Media from Dennis Urbaniak (of Sanofi-Aventis US). And, the finalists for the first Dosie Awards are announced.

JUST FOR FUN

Did you know that Niagara Falls once ran dry? True!

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

*****

Read Full Post »

Is Schering‘s contraceptive NuvaRing dangerous.? This article raises the question. My take – it’s always a yellow light for me when I see a journalistic heart-string approach based on an isolated (and unproven) incident. What sells newspapers is not the same as science.

Does this really need to be treated as a “new drug”? I have some real problems with this approach – AstraZeneca files NDA for Nexium + low-dose aspirin. Umm, folks, this is not a scientific advance. And patients are fully able to take an aspirin without needing an expensive purple coating over it…

BusinessWeek gives its list of the 10 most promising new drugs (due out over next 2 years). Fairly interesting if you’ve not been keeping up with pipelines – not much new information here, however.

——

Subscribe to the Impactiviti blog via e-mail

Subscribe to the Impactiviti blog via RSS

Connect with Steve Woodruff

Read Full Post »